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Primary testicular lymphoma is a rare and aggressive lymphoidmalignancy, most often representing diffuse large B-cell lymphomahistologically. Tumor-associated macrophages and tumor-infiltrat-
ing lymphocytes have been associated with survival in diffuse large B-
cell lymphoma, but their prognostic impact in primary testicular lym-
phoma is unknown. Here, we aimed to identify macrophages, their
immunophenotypes and association with lymphocytes, and translate
the findings into survival of patients with primary testicular lymphoma.
We collected clinical data and tumor tissue from 74 primary testicular
lymphoma patients, and used multiplex immunohistochemistry and
digital image analysis to examine macrophage markers (CD68, CD163,
and c-Maf), T-cell markers (CD3, CD4, and CD8), B-cell marker (CD20),
and three checkpoint molecules (PD-L1, PD-L2, and PD-1). We demon-
strate that a large proportion of macrophages (median 41%, range 0.08-
99%) and lymphoma cells (median 34%, range 0.1-100%) express PD-
L1. The quantity of PD-L1+CD68+ macrophages correlates positively
with the amount of PD-1+ lymphocytes, and a high proportion of either
PD-L1+CD68+ macrophages or PD-1+CD4+ and PD-1+CD8+ T cells trans-
lates into favorable survival. In contrast, the number of PD-L1+ lym-
phoma cells or PD-L1– macrophages do not associate with outcome. In
multivariate analyses with IPI, PD-L1+CD68+ macrophage and PD-1+
lymphocyte contents remain as independent prognostic factors for sur-
vival. In conclusion, high PD-L1+CD68+ macrophage and PD-1+ lympho-
cyte contents predict favorable survival in patients with primary testic-
ular lymphoma. The findings implicate that the tumor microenviron-
ment and PD-1 – PD-L1 pathway have a significant role in regulating
treatment outcome.  They also bring new insights to the targeted thera-
py of primary testicular lymphoma.
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ABSTRACT
Introduction
Primary testicular lymphoma (PTL) is a rare and aggressive lymphoid malignancy
affecting mainly elderly men.  The biology of PTL is beginning to emerge,1-7 and the
outcome has improved with the addition of anthracycline-based chemotherapy,
central nervous system (CNS) targeted therapy and irradiation of the contralateral
testis.8-10 The majority of PTLs represent diffuse large B-cell lymphoma (DLBCL)
displaying more often non-germinal center B-cell (GCB) than GCB-like signatures.11
Somatic mutations in NF-κ-B pathway genes, such as MYD88 and CD79B, as well
as rearrangements of programmed cell death ligand (PD-L) -1 and -2 genes, have
been shown to be enriched in PTL.2,4 In addition, two stromal signatures associated
with outcome have been described in primary, mainly
nodal DLBCL patients treated with immunochemothera-
py, forming the backbone for our study.12 We have recent-
ly demonstrated that tumor-associated macrophages
(TAMs) have a favorable prognostic impact on survival in
DLBCL patients after immunochemotherapy,13 whereas
other groups have investigated the role of programmed
cell death-1 (PD-1) pathway in DLBCL.14-18 While PD-1
protein is expressed predominantly by activated tumor-
infiltrating lymphocytes (TILs), its ligands (PD-L1 and PD-
L2) have been shown to be expressed both by the tumor
cells and the tumor microenvironment.15,19-21 An unexpect-
ed feature has been that PD-L1 expression by the tumor-
infiltrating myeloid and other immune cells can be more
prevalent than PD-L1 expression by the tumor cells.15,19,20
Recently, it was also shown that the expression of PD-L1,
not only by the tumor cells but also by the host cells, plays
a critical role in mediating the immunosuppressive func-
tion of the PD-1 pathway.21
In DLBCL, expression of PD-L1 by lymphoma cells has
been associated with poor outcome.14 Interestingly,
9p24.1/PD-L1/PD-L2 copy number alterations and addi-
tional translocations of these loci are frequent in PTLs
(>50%), leading to increased expression of the PD-Ls,4 and
possibly also to immune escape. Whether the expression
of PD-1 and PD-Ls predict survival in PTL, and in which
compartments, is unknown.
With the aim of resolving the relative expression of
checkpoint molecules by the tumor and host immune cells
in patients with PTL, we examined B cells, TAMs, TILs,
and checkpoint molecules by using multiplex immunohis-
tochemistry (mIHC),22 allowing simultaneous detection of
CD68+ TAMs, CD163+ or c-Maf+ M2-polarized TAMs,
CD4+ and CD8+ T cells, CD20+ B cells, and the checkpoint
molecules PD-L1, PD-L2 and PD-1. The findings were cor-
related with clinical parameters and survival.
Methods
Patients
We identified 74 PTL patients with DLBCL histology diagnosed
between the years 1987 and 2013 from the pathology databases of
the University Hospitals in Southern Finland. Histological diagno-
sis was established from surgical pretreatment tumor tissue
according to current criteria of the World Health Organization
(WHO) classification.23 The majority of the patients were treated
with anthracycline-based chemotherapy. About half of the
patients received rituximab as a part of their treatment.
Contralateral testis was treated with surgical excision or irradia-
tion for a minority of the patients. Patients were divided into three
equal tertiles, based on the content of different immune cell sub-
types (high, intermediate, low). The patient characteristics are
described in more detail in Table 1. The protocol and sampling
were approved by the Institutional Review Boards, Ethics
Committees and the Finnish National Supervisory Authority for
Welfare and Health.
Multiplex immunohistochemistry (mIHC)
Formalin-fixed, paraffin-embedded (FFPE) primary tumor tis-
sues were collected from the local biobanks and reviewed to
match the latest WHO classification.23 Selection of the cores on
the tissue microarray (TMA) was based on the evaluation of a
hematopathologist. TMA was constructed and the sections (3.5
µm) stained with 4-plex primary antibody panels (PD-L1, PD-L2,
CD68, c-MAF; CD3, CD4, CD8, PD-1; CD20, CD163, PD1, PD-
L1; Online Supplementary Table S1), followed by fluorescently
labelled secondary antibodies and DAPI counterstain (nuclear
stain). A more detailed description of the stainings is provided in
the Online Supplementary Methods. Fluorescent images were
acquired with AxioImager.Z2 (Zeiss, Germany). Machine-learning
platform CellProfiler24 2.1.2 was used for cell segmentation, inten-
sity measurements (upper quartile intensity) and immune cell clas-
sification. Different cell types were quantified as proportion to all
cells (e.g., PD-L1⁺CD68⁺ implying the number of PD-L1⁺CD68⁺
TAMs from all cells in a TMA spot) or as a proportion to a specific
cell subtype (e.g., PD-L1⁺CD68⁺/CD68⁺ implying the number of
PD-L1⁺CD68⁺ cells from all CD68⁺ TAMs). Spots with less than
5000 cells were excluded from the analysis, and data from dupli-
cate spots from the same patient were merged. 
Gene expression analysis
CD68, CD163, MAF, MS4A1 (CD20), CD274 (PD-L1),
PDCD1LG2 (PD-L2), and PDCD1 (PD-1) mRNA levels were
measured from 60 PTL samples using digital gene expression
analysis with NanoString nCounter (Nanostring Technologies,
Seattle, WA, USA).25
Survival definitions and statistical analyses
Overall survival (OS) was defined as time between diagnosis
and death from any cause, disease specific survival (DSS) as time
between diagnosis and lymphoma related death, and progression
free survival (PFS) as time between diagnosis and lymphoma pro-
gression or death from any cause.
Statistical analyses were performed with IBM SPSS v.24.0 (IBM,
Armonk, NY, USA). Differences in the frequency of prognostic
factors between three patient groups were analyzed by Kruskal-
Wallis test. Correlations between gene expression values and cell
counts as well as between different immune cell subpopulations
were tested with Spearman's rank correlation. 
Survival rates were estimated using the Kaplan–Meier method.
Univariate and multivariate analyses were performed according to
the Cox proportional hazards regression model. The potential bias
due to duration of follow up was assessed by Schoenfeld residual.
Probability values below 0.05 were considered statistically signifi-
cant. All comparisons and all comparative tests were two-tailed.
Results
Patient characteristics
Patient and treatment characteristics of the study cohort
are shown in Table 1. The majority of the patients repre-
sented non-GCB phenotype, low stage, and had
low/intermediate International Prognostic Index (IPI).
Altogether, 34 deaths, 24 relapses and 24 lymphoma-asso-
ciated deaths occurred during the median follow up of 67
months (range from 6.7 to 120 months). Five-year OS,
DSS and PFS rates were 56%, 68%, and 53%, respectively. 
Association of CD68, PD-L1 and PD-L2 encoding gene
expression with survival
First, we determined the gene expression of the
macrophage markers (CD68, CD163 and MAF), check-
point molecules CD274 (PD-L1), PDCD1LG2 (PD-L2) and
PDCD1 (PD-1), and the B-cell marker MS4A1 (CD20).
CD68 expression correlated positively with CD274
(rs=0.654, P<0.001), PDCD1LG2 (rs=0.636, P<0.001),
CD163 (rs=0.602, P<0.001), and MAF (rs=0.425, P=0.001)
levels, and to a lesser extent with PDCD1 (rs=0.300,
P=0.020), whereas no correlation between CD68 and
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MS4A1 expression was found. Furthermore, the expres-
sion of CD68, CD274 and PDCD1LG2 genes analyzed as
continuous variables, but not PDCD1, CD163 or MAF,
translated into favorable survival (Table 2). 
High PD-L1+ TAM content predicts favorable survival
To explore the expression of the checkpoint molecules
in the tumor cells and in the microenvironment in more
detail, we analyzed the cell immunophenotypes with
mIHC from a PTL TMA using four primary antibodies and
DAPI (nuclear stain) simultaneously (Figure 1A-C; see also
Table 1 for the TMA cohort used and Online Supplementary
Table S1 for the antibody panels). The marker CD68 was
used to identify all TAMs. Subpopulations of TAMs were
defined by the presence and absence of CD163, c-MAF,
PD-L1 and PD-L2 (Figure 1A-B, D). In addition, CD20
marker was used to identify lymphoma cells (Figure 1B).
For detecting TILs, a panel with CD3, CD4, CD8, and PD1
antibodies was used (Figure 1C). 
As proof of concept, we found high agreement with the
gene expression and the mIHC data when analyzing the
quantities of CD68+ macrophages (rs=0.637, P<0.001),
lymphoma cells (rs=0.704, P<0.001) and PD-L1
+ cells
(rs=0.710, P<0.001) (Online Supplementary Figure S1). The
proportions of the different cell types in the tumor tissue
are shown in Figure 1D. The most prominent non-malig-
nant cell type was CD3+ T-lymphocyte (median 45%,
range 5-97%).  TAM and PD-L1+ cell contents showed a
great variation between the samples (CD68+ TAMs, medi-
an 23%, range 3-81%; PD-L1+ cells, median 15%, range
0.01-100%), and a large proportion of lymphoma cells
(median 34%, range 0.1-100%) and TAMs (median 41%,
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Table 1. Patient and treatment characteristics.
All n (%) PD-L1+ PD-L1+ PD-L1+
CD68+ CD68+ CD68+ P
low intermed. high
Number of patients 74 25 (34) 24 (32) 25 (34)
Median age (range) 70 (36-92) 68 (38-86) 73 (37-92) 66 (46-90)
Age
<60, years 17 (23) 6 (24) 4 (17) 7 (28) 0.638
≥ 60, years 57 (77) 19 (76) 20 (83) 18 (72)
Molecular subgroup
GCBa 17 (23) 8 (32) 4 (17) 5 (20) 0.426
Non-GCB 56 (76) 17 (68) 20 (83) 19 (76)
NA 1 (1) 1 (4)
Stage
I-II 47 (64) 10 (40) 16 (67) 21 (84) 0.002
III-IV 24 (32) 15 (60) 6 (25) 3 (12)
NA 3 (4) 2 (8) 1 (4)
IPI score
0-2 50 (68) 13 (52) 17 (71) 20 (80) 0.065
3-5 20 (27) 11 (44) 5 (21) 4 (16)
NA 4 (5) 1 (4) 2 (8) 1 (4)
CNS prophylaxis 36 (49) 9 (36) 11 (46) 16 (64) 0.137
IV prophylaxis 34 (46) 8 (32) 10 (42) 16 (64) 0.057
IT prophylaxis 7 (9) 2 (8) 3 (13) 2 (8) 0.856
Contralateral testis treated 23 (31) 6 (24) 7 (29) 10 (40) 0.464
Irradiation 12 (16) 2 (8) 3 (13) 7 (28) 0.136
Surgical excision 11 (15) 4 (16) 4 (17) 3 (12) 0.884
Anthracycline-based chemotherapy 60 (81) 18 (72) 21 (88) 21 (84) 0.305
Treated with rituximab 35 (47) 9 (36) 11 (46) 15 (60) 0.237
Relapse of contralateral testis 1 (1) 0 (0) 1 (4) 0 (0) 0.377
CNS progression 9 (12) 4 (16) 4 (17) 1 (4) 0.312
aGCB: germinal center B-cell like; NA: not applicable; IPI: International prognostic Index; CNS: central nervous system; IV: intravenous; IT: intrathecal; P: P-value determined by
Kruskal-Wallis test.
Table 2. Cox regression analysis at the univariate level showing asso-
ciation of gene expression levels with overall survival. 
Gene symbol HRa 95% CI P
CD68 0.505 0.290-0.881 0.016
CD274 0.737 0.592-0.919 0.007
PDCD1LG2 0.688 0.505-0.936 0.017
PDCD1 0.846 0.659-1.088 0.192
CD163 0.914 0.636-1.313 0.627
MAF 0.899 0.551-1.466 0.668
aHR: hazard ratio; CI: confidence interval. Boldface font indicates statistical signifi-
cance (P<0.05).
range 0.1-99%) expressed PD-L1. Due to a low proportion
of PD-L2+ cells (0.06%) (data not shown), PD-L2 was
excluded from further analyses. 
We further observed that a high number of PD-L1+ cells,
high proportion of PD-L1+CD68+ macrophages from all
cells, as well as a high proportion of PD-L1+CD68+
macrophages from all CD68+ macrophages (PD-
L1+CD68+/CD68+), associated with favorable OS when
analyzed as continuous variables (Table 3). In order to use
an objective cutoff, we stratified the patients into three
equal subgroups based on tertiles of the PD-L1⁺CD68⁺
macrophage counts (high, intermediate, low). The 5-year
OS and DSS rates were clearly worse for the patients with
a low number of PD-L1⁺CD68⁺ macrophages (≤4.75%
corresponding to the lowest tertile of the patients) in com-
parison to the patients with intermediate or high numbers
(>4.75%, 5-y OS, 39% vs. 66%, P=0.014; 5-y DSS, 53% vs.
76%, P=0.056; Figure 2A). When PD-L1⁺CD68⁺
macrophage count was included in a multivariate analysis
with IPI, both factors had independent prognostic value
for OS (Table 4). In contrast, neither PD-L1+ lymphoma
cells, PD-L1+CD68– cells nor any other TAM phenotypes
were significantly associated with survival (Table 3).
When comparing the three PD-L1+CD68+ TAM subgroups
(high, intermediate and low), no significant differences in
age, molecular subtype, IPI score or treatments were
observed (Table 1). However, high PD-L1+CD68+
macrophage count was associated with limited disease
stage. When the patients treated in the pre-rituximab era
were removed from the analyses, a trend towards worse
survival was maintained for the patients with low number
of PD-L1+CD68+ macrophages (≤5.97%, the lowest tertile;
OS, P=0.093, Online Supplementary Figure S2A). These
results highlight the clinical relevance and possible func-
tional connection of PD-L1+ TAMs for PTL progression.  
Association of PD1+ TILs with survival
Given the prognostic value of PD-L1+ TAMs, we then
determined their association with T cells by mIHC. The
marker CD3 was used to identify all T cells.
Subpopulations of T cells were then defined by the pres-
Tumor-associated macrophages in PTL
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Figure 1. Characterization of cell immunophenotypes with mIHC. (A-C) Representative images from 4-plex mIHC stainings. Panels (low, intermediate, and high) show
representative images from the corresponding tertiles, based on the content of different immune cell subtypes. The insets highlight cells with higher magnification.
PD-L1=blue, PD-L2=red, CD68=white, c-Maf=green (A); PD-L1=blue, CD163=red, CD20=white, PD1=green (B); CD3=blue, CD8=red, CD4=white, PD1=green (C).
Scale bar 40 mm. (D) Proportions of distinct immune cell subpopulations from all cells. PD-L1+CD68+ indicating the content of PD-L1+ TAMs, PD-L1+CD163+ and PD-
L1+CD68+c-Maf+ the content of PD-L1+ M2-polarized TAMs, PD-1+CD3+CD4+ and PD-1+CD3+CD8+ the content of PD-1+ TILs, and PD-L1+CD20+ the content of PD-L1+
lymphoma cells.
Table 3. Cox regression analysis at the univariate level showing asso-
ciation of cell immunophenotypes with overall survival.
Cell immunophenotype HRa 95% CI P
PD-L1+ 0.983 0.967-0.999 0.038
CD20+ 1.009 0.995-1.023 0.209
PD-L1+CD20+ 0.993 0.978-1.008 0.376
PD-L1+CD68- 0.981 0.955-1.007 0.146
CD68+ 0.986 0.964-1.008 0.196
PD-L1+CD68+ 0.965 0.933-0.999 0.042
PD-L1+CD68+/CD68+ 0.987 0.975-0.998 0.027
PD-L1–CD68+ 1.012 0.982-1.043 0.437
CD68+c-Maf+ 0.835 0.668-1.044 0.113
PD-L1+CD68+c-Maf+ 0.734 0.518-1.041 0.083
CD163+ 0.996 0.978-1.014 0.666
PD-L1+CD163+ 0.989 0.969-1.010 0.298
CD3+ 0.194 0.053-0.712 0.013
PD-1+CD3+CD4+ 0.089 0.008-0.999 0.050
PD-1+CD3+CD8+ 0.042 0.003-0.537 0.015
aHR: hazard ratio; CI: confidence interval; PD-L1+CD68+ implies the number of PD-
L1+CD68+ TAMs from all cells; PD-L1+CD68+/CD68+ implies the number of PD-L1+CD68+
TAMs from all CD68+ TAMs.  Boldface font indicates statistical significance (P<0.05). 
A
B
C
D
ence and absence of CD4, CD8 and PD-1 (Figure 1C-D).
As with CD4+ T-helper and CD8+ cytotoxic cells in gener-
al, PD-1+CD3+CD4+ and PD-1+CD3+CD8+ T-cell counts
correlated with the PD-L1+ TAM counts (Online
Supplementary Table S2). Furthermore, as overall with 
T-cells,25 a high and intermediate number of PD-1+ CD4+
and CD8+ T-cells associated with superior survival (PD-
1+CD3+CD4+ cells ≤5.7% corresponding to the lowest ter-
tile vs. other patients; 5-y OS, 34% vs. 68%, P=0.002; 5-y
DSS, 43% vs. 81%, P<0.001; PD-1+CD3+CD8+ cells, ≤7.2%
corresponding to the lowest tertile vs. other patients; 5-y
OS, 39% vs. 65%, P=0.008; 5-y DSS, 43% vs. 81%,
P<0.001; Figures 2B-C). In multivariate analyses with IPI,
both PD-1+CD3+CD4+ and PD-1+CD3+CD8+ T-cell counts
maintained an independent association with OS (Table 4).
When the patients treated in the pre-rituximab era were
removed from the analyses, a low number of PD-1+ T cells
maintained their adverse impact on survival (PD-
1+CD3+CD4+ cells, ≤8.50%, the lowest tertile; OS, P=0.001
and PD-1+CD3+CD8+ cells, ≤11.02%, the lowest tertile;
OS,  P=0.034; Online Supplementary Figure S2B-C). 
Discussion
In this study, we applied mIHC and digital image analy-
sis to a TMA comprised of PTL tissue from 74 patients.
We show that PTL microenvironment contains a hetero-
geneous TAM population. Among these, PD-L1+ TAMs
were the predominant subpopulation, and high infiltra-
tion of PD-L1+CD68+ TAMs was associated with favorable
survival.  Additionally, PD-1+ CD4+ and CD8+ TIL contents
correlated with PD-L1+ TAM infiltration and survival, and
both PD-L1+ TAMs and PD-1+ TILs emerged as independ-
ent indicators of survival for the patients with PTL. In con-
trast, neither PD-L1+ lymphoma cells, other PD-L1+ cells
M. Pollari et al.
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Figure 2. Association of the immune cell subtypes with survival. (A-C) Cell immunophenotypes were determined by mIHC from 74 PTL patients. Patients were strat-
ified into three equal subgroups (high, intermediate and low) based on tertiles of PD-L1+CD68+ TAM, PD-1+CD3+CD4+ T cell, and PD-1+CD3+CD8+ T-cell counts. Kaplan-
Meier plots depict survival differences between the PD-L1+CD68+ (A), PD-1+CD3+CD4+ (B), and PD-1+CD3+CD8+ (C) groups. P-values were determined by univariate
Cox regression analysis (HR, hazard ratio with 95% confidence interval).
Table 4. Cox regression analysis at multivariate level showing inde-
pendent association of low cell immunophenotypes and IPI high 
(IPI 3-5) with overall survival.
Cell immunophenotype              HRa               95% CI                    P
PD-L1+CD68+                                   2.214              1.054-4.650                  0.036
IPI                                                      4.325              2.008-9.312                 <0.001
PD-L1+CD68+/CD68+                       2.275              1.054-4.909                  0.036
IPI                                                      3.608              1.643-7.923                  0.001
PD-1+CD3+CD4+                              2.654              1.261-5.586                  0.010
IPI                                                      4.907             2.275-10.585                <0.001
PD-1+CD3+CD8+                              2.259              1.075-4.748                  0.031
IPI                                                      4.971             2.314-10.678                <0.001
aHR, hazard ratio; CI: confidence interval; IPI: International Prognostic Index.
A B C
than TAMs, nor other TAM phenotypes correlated with
survival. The findings highlight the specific roles of TAMs,
TILs and PD-1-PD-L1 axis in regulating survival and ther-
apy resistance in PTL. 
mIHC is a novel technology enabling multi-parametric
readout from a single tissue section. In our study, the
simultaneous use of multiple markers is important in
many ways. Firstly, while PD-L1 was found to be
expressed both in TAMs and B cells including lymphoma
cells, the prognostic impact of PD-L1 positivity was
restricted to TAMs. Thus, the use of just one marker
would not be able to detect the survival association.
Secondly, the spatial relationships between TILs, TAMs
and lymphoma cells are retained in our experimental strat-
egy, allowing for a more precise appreciation of their bio-
logical interactions. Thirdly, since mIHC was performed
on all evaluable PTL tissue areas on the TMA, thereby
providing an overall snapshot of the PTL microenviron-
ment, we can avoid a bias of earlier observations focusing
only on hot spot areas of immune cell counts using single
marker immunohistochemistry. However, it should be
noted that while the overall infiltration of PD-L1+ TAMs
and PD-1+ TILs had a significant impact on survival, their
functional statuses remain to be explored. Combining our
panel with other multiplex panels for immunoregulatory
molecules, such as FoxP3, LAG-3 or IDO-1 and IDO-2,
may be useful in the evaluation of response to
immunotherapy.
As described in a recent review article by Xu-Monette et
al., the PD-L1 expression in the tumor microenvironment
has not been previously well defined in B-cell lymphomas,
and association with survival has not been demonstrat-
ed.18 PD-1 is a protein, which is classically upregulated
upon activation of T lymphocytes. Interaction between
PD-1 and PD-L1 was previously thought to induce
immune tolerance by leading T lymphocytes to
apoptosis.26 Further studies have, however, revealed that
the expression of PD-L1 on tumor cells can lead to
immune escape, to T-cell exhaustion and a state of non-
responsiveness, further enabling immune escape of the
tumor cells.27-29 Moreover, in addition to binding to PD-1,
PD-L1 and PD-L2 can also bind to CD80/B7-1 (PD-L1)30,31
and RGMb (PD-L2),32 indicating that the PD-1 – PD-L1
pathway is much more complex than previously anticipat-
ed.18
In addition to PD-L1, macrophages express PD-1.33,34
Recently, Gordon and coworkers showed that PD-1
expression by TAMs inhibits phagocytosis and tumor
immunity.35 In addition, they demonstrated that blockade
of PD-1 – PD-L1 interaction increases macrophage phago-
cytosis, reduces tumor growth and lengthens survival in
mouse models of colon cancer, suggesting the PD-1 – PD-
L1 pathway has a significant role in TAM function and
tumor survival.
Based on our findings, we suggest that the PD-1 - PD-L1
signaling between TAMs and TILs has clinical relevance in
PTL. As PD-1 engagement on T cells to its ligands has
been linked to decreased anti-tumor immunity, and early
experience on PD-1 blockade in PTL has shown promising
results,36 the association of high PD-L1+ TAM and PD-1+ T-
cell count with favorable outcome in response to
immunochemotherapy seems paradoxical. Yet, the inter-
action of PD-L1+ TAMs and PD-1+ T cells might modify
the tumor microenvironment in PTL, or otherwise pro-
mote an anti-tumor immune response following
immunochemotherapy.
In conclusion, we argue that high PD-L1+ TAM and 
PD-1+ T-cell counts correlate with each other and with
favorable outcome in patients with PTL. Higher PD-
L1+CD68+ TAM scores seem to protect the patients from
progression and death, and identify a group of patients
with favorable prognosis. Interestingly, apart from 
PD-L1+CD68+ TAMs, no association was found between
other PD-L1+ cells or PD-L1– TAMs and survival. Together,
the data demonstrate that the PD-1 - PD-L1 axis in PTL
affects the survival of patients with PTL.  
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